Literature DB >> 8592166

Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells.

E Sadot1, D Gurwitz, J Barg, L Behar, I Ginzburg, A Fisher.   

Abstract

Hyperphosphorylated tau proteins are the principal fibrous component of the neurofibrillary tangle pathology in Alzheimer's disease. The possibility that tau phosphorylation is controlled by cell surface neurotransmitter receptors was examined in PC12 cells transfected with the gene for the rat m1 muscarinic acetylcholine receptor. Stimulation of m1 receptor in these cells with two acetylcholine agonists, carbachol and AF102B, decreased tau phosphorylation, as indicated by specific tau monoclonal antibodies that recognize phosphorylation-dependent epitopes and by alkaline phosphatase treatment. The muscarinic effect was both time and dose dependent. In addition, a synergistic effect on tau phosphorylation was found between treatments with muscarinic agonists and nerve growth factor. These studies provide the first evidence for a link between the cholinergic signal transduction system and the neuronal cytoskeleton that can be mediated by regulated phosphorylation of tau microtubule-associated protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8592166     DOI: 10.1046/j.1471-4159.1996.66020877.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  32 in total

1.  Protein τ-mediated effects on rat hippocampal choline transporters CHT1 and τ-amyloid β interactions.

Authors:  Zdena Kristofikova; Daniela Ripova; Katerina Hegnerová; Jana Sirova; Jiri Homola
Journal:  Neurochem Res       Date:  2013-07-04       Impact factor: 3.996

2.  GRK5 deficiency accelerates {beta}-amyloid accumulation in Tg2576 mice via impaired cholinergic activity.

Authors:  Shaowu Cheng; Longxuan Li; Shuangteng He; Jun Liu; Yuning Sun; Minchao He; Kenneth Grasing; Richard T Premont; William Z Suo
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

3.  Microtubule cytoskeleton involvement in muscarinic suppression of voltage-gated calcium channel current in guinea-pig ileal smooth muscle.

Authors:  T Unno; S Komori; H Ohashi
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 4.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

Authors:  M L Billingsley; R L Kincaid
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

Review 5.  Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease.

Authors:  A I Levey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

6.  Cholinergic Mechanisms in the Cerebral Cortex: Beyond Synaptic Transmission.

Authors:  Saak V Ovsepian; Valerie B O'Leary; Laszlo Zaborszky
Journal:  Neuroscientist       Date:  2015-05-22       Impact factor: 7.519

Review 7.  G Protein-Coupled Receptor Kinases in the Inflammatory Response and Signaling.

Authors:  Michael D Steury; Laura R McCabe; Narayanan Parameswaran
Journal:  Adv Immunol       Date:  2017-06-10       Impact factor: 3.543

8.  A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides.

Authors:  Qiang Liu; Yao Huang; Fenqin Xue; Alain Simard; Jamie DeChon; Guohui Li; Jianliang Zhang; Linda Lucero; Min Wang; Michael Sierks; Gang Hu; Yongchang Chang; Ronald J Lukas; Jie Wu
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

Review 9.  Tau function and dysfunction in neurons: its role in neurodegenerative disorders.

Authors:  Jesús Avila; Filip Lim; Francisco Moreno; Carlos Belmonte; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

Review 10.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.